Recent

% | $
Quotes you view appear here for quick access.

Pacific Biosciences of California, Inc. Message Board

berlin20210 6 posts  |  Last Activity: Jun 5, 2015 7:06 AM Member since: Feb 20, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Biotechnology Value Fund L P has filled a SC 13G/A form regarding Arqule Inc 1.83 -0.07 -3.68%. Filing Link: 000092189515001488. Per Biotechnology Value Fund L P’s filing, the filler reported increased stake in the company by 25.68% to 6,356,118 shares. Biotechnology Value Fund L P now owns 10.1% of the Health Care-company. This form was required due to trading activity on May 26, 2015.

    Sentiment: Strong Buy

  • Zacks Rating on Sequenom, Inc.

    Sentiment: Strong Buy

  • berlin20210 by berlin20210 May 27, 2015 8:13 AM Flag

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Notice of Effectiveness
    Effectiveness Date: May 26, 2015 4:00 P.M.
    Form: S-3
    CIK: 0001325879
    Company Name: AVEO PHARMACEUTICALS INC
    File Number: 333-203932

    Sentiment: Strong Buy

  • berlin20210 by berlin20210 May 18, 2015 4:14 AM Flag

    Sequenom Inc. (NASDAQ:SQNM) shares moved down -3.15% in last trading session and ended the day at $3.69. SQNM Gross Margin is 44.90% and its return on assets is 0.70%. Sequenom Inc. (NASDAQ:SQNM) quarterly performance is 1.93%. On 7 May, Sequenom Inc. (NASDAQ:SQNM) said that, fees and royalties from the noninvasive prenatal test patent pool it shares with Illumina is expected to make up an increasing share of its revenues in coming quarters.

    Sentiment: Strong Buy

  • Oppenheimer reiterated their buy rating on shares of Sequenom (NASDAQ:SQNM) in a research report released on Friday morning.

    A number of other analysts have also recently weighed in on SQNM. Analysts at Wedbush downgraded shares of Sequenom from an outperform rating to a neutral rating in a research note on Thursday. Separately, analysts at Zacks downgraded shares of Sequenom from a buy rating to a hold rating in a research note on Wednesday. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Sequenom currently has a consensus rating of Buy and a consensus price target of $5.50.

    Sentiment: Strong Buy

  • Sequenom Receives Buy Rating from Oppenheimer (SQNM)

    Posted by Jim Brewer on May 8th, 2015 // No Comments
    Share on StockTwits

    Sequenom, Inc. logoOppenheimer reiterated their buy rating on shares of Sequenom (NASDAQ:SQNM) in a research report released on Friday morning.

    A number of other analysts have also recently weighed in on SQNM. Analysts at Wedbush downgraded shares of Sequenom from an outperform rating to a neutral rating in a research note on Thursday. Separately, analysts at Zacks downgraded shares of Sequenom from a buy rating to a hold rating in a research note on Wednesday. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Sequenom currently has a consensus rating of Buy and a consensus price target of $5.50.

    Sentiment: Strong Buy

PACB
5.20-0.21(-3.88%)Jul 2 4:00 PMEDT